Biofrontera (BFRI) to Release Quarterly Earnings on Wednesday

Biofrontera (NASDAQ:BFRI) will likely be posting its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Biofrontera to post earnings of ($0.60) per share and revenue of $7.00 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 10:00 AM ET.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.12). Biofrontera had a negative return on equity of 1,104.09% and a negative net margin of 42.34%.The business had revenue of $9.03 million during the quarter, compared to analysts’ expectations of $8.30 million. On average, analysts expect Biofrontera to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biofrontera Price Performance

NASDAQ:BFRI opened at $1.08 on Monday. Biofrontera has a 52 week low of $0.54 and a 52 week high of $1.87. The company has a quick ratio of 0.75, a current ratio of 0.96 and a debt-to-equity ratio of 8.99. The company has a market capitalization of $10.95 million, a P/E ratio of -0.57 and a beta of 0.55. The stock’s fifty day moving average is $0.97 and its two-hundred day moving average is $0.85.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biofrontera in a research report on Thursday, October 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $2.75.

Hedge Funds Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. grew its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera comprises about 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest position. Rosalind Advisors Inc. owned about 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. 10.08% of the stock is owned by institutional investors and hedge funds.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.